evidence table

Sodium Potassium Blood Pressure Guideline Evidence Table

Structured evidence table for Sodium Potassium Blood Pressure Guideline, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Sodium Potassium Blood Pressure GuidelineIn contrast, clinically relevant arrhythmic risk typically arises only when values exceed 6.0 mmol/L, which represents an absolute contraindication to potassium-raising drugs, a level that occurs normally only in the presence of acidosis or advanced renal dysfunction [].2Bellicini Maria Giulia (2026)Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
Sodium Potassium Blood Pressure GuidelineMore recent studies with finerenone for diabetic kidney disease (FIDELIO-DKD, FIGARO-DKD) confirmed that even high-risk patients could be managed safely with appropriate monitoring [,].2Bellicini Maria Giulia (2026)Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
Sodium Potassium Blood Pressure GuidelineIf glucose levels are normal, the filtered load of glucose is small, and these agents simply do not act; there is no further glycosuria and thus no risk of hypoglycemia in patients not treated with insulin.2Bellicini Maria Giulia (2026)Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
Sodium Potassium Blood Pressure GuidelineWhen appropriately initiated, up-titrated, and combined, these therapies reduce all-cause mortality by approximately [,].2Bellicini Maria Giulia (2026)Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
Sodium Potassium Blood Pressure GuidelineEven mild elevations in serum potassium are associated with increased risks of arrhythmia, hospitalization, and mortality, underscoring the importance of effective potassium management.3Jung Jinah (2026)Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
Sodium Potassium Blood Pressure Guideline2 3 4 Beyond its direct clinical risks, hyperkalemia represents a major barrier to the optimal implementation of guideline-directed medical therapy for cardiorenal disease.3Jung Jinah (2026)Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
Sodium Potassium Blood Pressure GuidelineObservational studies consistently demonstrate that RAASi discontinuation following hyperkalemia is associated with worse cardiovascular and renal outcomes, highlighting the clinical importance of maintaining potassium homeostasis while preserving life-saving pharmacotherapy [].3Jung Jinah (2026)Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
Sodium Potassium Blood Pressure Guideline1 Hyperkalemia is a frequent and clinically significant complication in patients with chronic kidney disease (CKD), heart failure (HF), and diabetes mellitus.3Jung Jinah (2026)Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
topicSodium Potassium Blood Pressure Guideline
claimIn contrast, clinically relevant arrhythmic risk typically arises only when values exceed 6.0 mmol/L, which represents an absolute contraindication to potassium-raising drugs, a level that occurs normally only in the presence of acidosis or advanced renal dysfunction [].
evidence level2
citationBellicini Maria Giulia (2026)
sourceBradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
topicSodium Potassium Blood Pressure Guideline
claimMore recent studies with finerenone for diabetic kidney disease (FIDELIO-DKD, FIGARO-DKD) confirmed that even high-risk patients could be managed safely with appropriate monitoring [,].
evidence level2
citationBellicini Maria Giulia (2026)
sourceBradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
topicSodium Potassium Blood Pressure Guideline
claimIf glucose levels are normal, the filtered load of glucose is small, and these agents simply do not act; there is no further glycosuria and thus no risk of hypoglycemia in patients not treated with insulin.
evidence level2
citationBellicini Maria Giulia (2026)
sourceBradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
topicSodium Potassium Blood Pressure Guideline
claimWhen appropriately initiated, up-titrated, and combined, these therapies reduce all-cause mortality by approximately [,].
evidence level2
citationBellicini Maria Giulia (2026)
sourceBradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
topicSodium Potassium Blood Pressure Guideline
claimEven mild elevations in serum potassium are associated with increased risks of arrhythmia, hospitalization, and mortality, underscoring the importance of effective potassium management.
evidence level3
citationJung Jinah (2026)
sourceAdvances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
topicSodium Potassium Blood Pressure Guideline
claim2 3 4 Beyond its direct clinical risks, hyperkalemia represents a major barrier to the optimal implementation of guideline-directed medical therapy for cardiorenal disease.
evidence level3
citationJung Jinah (2026)
sourceAdvances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
topicSodium Potassium Blood Pressure Guideline
claimObservational studies consistently demonstrate that RAASi discontinuation following hyperkalemia is associated with worse cardiovascular and renal outcomes, highlighting the clinical importance of maintaining potassium homeostasis while preserving life-saving pharmacotherapy [].
evidence level3
citationJung Jinah (2026)
sourceAdvances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
topicSodium Potassium Blood Pressure Guideline
claim1 Hyperkalemia is a frequent and clinically significant complication in patients with chronic kidney disease (CKD), heart failure (HF), and diabetes mellitus.
evidence level3
citationJung Jinah (2026)
sourceAdvances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate

Learn next

Related evidence and supplement guides

GuidePotassium Blood Pressure Randomized Trial: What the Evidence SaysPotassium Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence...GuideChokeberry Blood Pressure Randomized Trial: What the Evidence SaysChokeberry Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence...GuideOmega-3 Blood Pressure Meta-analysis: What the Evidence SaysOmega-3 Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence datab...GuideHibiscus Blood Pressure Randomized Trial: What the Evidence SaysHibiscus Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence d...AnswerDoes Chokeberry Blood Pressure Randomized Trial work?Chokeberry Blood Pressure Randomized Trial has evidence relevant to strength of evidence and wha...AnswerIs Chokeberry Blood Pressure Randomized Trial safe?Chokeberry Blood Pressure Randomized Trial has evidence relevant to safety, limits, and clinicia...AnswerWhat does the evidence say about Chokeberry Blood Pressure Randomized Trial?Chokeberry Blood Pressure Randomized Trial has evidence relevant to benefits, uncertainty, and p...AnswerDoes Omega-3 Blood Pressure Meta-Analysis work?Omega-3 Blood Pressure Meta-Analysis has evidence relevant to strength of evidence and what the...

Source documents

  1. Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry
  2. Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate